Bern Human Organoid-Study to Study Host-microbe Interaction

NCT05323357 | Recruiting

• 1 other identifier: 2021-01865
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The human body inhabits a complex consortium of different microbes which together form the microbiota. Virtually every surface of the human body is colonized by a distinct microbiota, forming complex communities. An increasing number of research results indicates that changes in the microbiota can have vast effects on the health of its host. Most studies investigating the microbiota were conducted on animals, as many interventions and investigations cannot be performed on humans due to ethical considerations. This raises the question if findings from experimental studies are translational and can benefit patients. That becomes especially apparent when trying to dissect molecular mechanisms involved in this fine-tuned interplay between nutrients, the microbiota, and its host. By establishing human organoid cultures from the large and small intestine that can be exposed to microbes and/or microbial products with subsequent transcriptomic, epigenetic and immunological analysis, the investigators aim to generate findings with high translational potential with new insights into the complex interaction of the microbiota, the host and its immune system.

Conditions

Organoids; Allergy and Immunology; Microbiota

Keywords

Enteroids; Host-Microbiota; Mucosal Immunology

Outcome Measures

Primary Outcomes (4)

• Assessment of changes in the transcriptomic profile of epithelial cells before and after organoid culture

  Assessment of changes in the transcriptomic profile of epithelial cells before and after organoid culture is established by RNA-sequencing and quantitative polymerase chain reaction (qPCR)

  3 Years

• Assessment of changes in the epigenome of epithelial cells before and after organoid culture

  Assessment of changes in the epigenome of epithelial cells before and after organoid culture is established by whole genome bisulphite sequencing and chromatin immunoprecipitation sequencing

  3 Years

• Transcriptomic and Epigenomic Landscape of host-microbiota Interaction

  Determining effects of microbial-derived metabolites on the transcriptomic and epigenomic landscape of human organoids treated with the respective metabolite

  3 Years

• Host-Microbiota interaction - Stem cell maintenance and Cell Differentiation

  Determining effects of microbial-derived metabolites on epithelial cell differentiation and stem cell maintenance

  3 Years

Secondary Outcomes (2)

• 3D-to-2D Transwell System

  3 Years

• Gut-on-a-chip

  3 Years

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

1. Patients undergoing routine ileo-colonoscopy without sign of inflammation, dysplasia, or neoplasia in histology 2. Patients undergoing routine gastro-duodenoscopy without sign of inflammation, dysplasia, or neoplasia in histology

You may qualify if:

• Signed informed consent
• Indication for upper or lower endoscopic procedure
• Ability to understand and follow study procedures and understand informed consent
• Age 18-80 years
• Negative pregnancy test result prior to study enrollment of female study participants (test will be performed prior to enrollment)
• BMI between 18.5 and 30 kg/m2

You may not qualify if:

• Disease known to chronically affect gut microbiota, gut epithelium or gut-associated immune system, namely inflammatory bowel disease, diverticulitis, microscopic colitis, liver cirrhosis, malignancy within the digestive tract, systemic sclerosis, coeliac disease, common-variable immunodeficiency, diabetes mellitus
• Medication with immunosuppressants (e.g. corticoids, biological therapy)
• Current diagnosis of a hematological disorder (e.g. anemia with hemoglobin \<7 g/dl, leukemia) or any other absolute contraindication for blood draw
• Women who are pregnant
• Serious coagulation disorder, relevant thrombocytopenia (\<50'000/ul), double platelet-inhibition, oral anticoagulation (ASS therapy is possible)
• Known or suspected non-compliance, drug, or alcohol abuse
• Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant
• Previous enrolment into the current study
• Enrolment of the investigator, his/her family members, employees, and other dependent persons
• Inability or unwillingness to provide blood samples and tissue samples (biopsies)
• Participants taking oral anticoagulant or with bleeding disorders who would be at much higher risk of bleeding after biopsy samples or who are contraindicated for an endoscopic examination
• Patients unable to give informed consent
• Patients that have been under antibiotic therapy in the last 4 weeks
• Participation in other clinical study interfering with study procedures
• Potential study participants that wish not to be informed about random results acquired during the study (e.g., during endoscopy or genetic analysis) relevant for their health and for prevention of diseases

Sponsors & Collaborators

• Insel Gruppe AG, University Hospital Bern: lead
• University of Bern: collaborator

Study Sites (1)

Inselspital, University Hospital Bern

Bern, 3010, Switzerland

RECRUITING

Related Publications (1)

• Pleguezuelos-Manzano C, Puschhof J, van den Brink S, Geurts V, Beumer J, Clevers H. Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells. Curr Protoc Immunol. 2020 Sep;130(1):e106. doi: 10.1002/cpim.106.

  PMID: 32940424 BACKGROUND

Related Links

• Pleguezuelos-Manzano C et al. 2020

Biospecimen

Retention: SAMPLES WITH DNA

Biopsies from the Duodenum (routine Gastroscopy), Ileum (routine Colonoscopy) or Colon (routine Colonoscopy)

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

• Stephanie Ganal-Vonarburg, Prof

  Inselspital, University Hospital Bern

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Stephanie Ganal-Vonarburg, Prof. Dr.

CONTACT

+41 31 632 59 00; bauchzentrum@insel.ch

Sandro Christensen

CONTACT

+41 31 684 16 47; sandro.christensen@unibe.ch

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2022
• First Posted: April 12, 2022
• Study Start: March 31, 2022
• Primary Completion: March 30, 2025
• Study Completion: March 30, 2026
• Last Updated: December 11, 2024

Record last verified: 2024-12

Locations

CH (1)